Sign in
LH

LifeStance Health Group, Inc. (LFST)·Q2 2024 Earnings Summary

Executive Summary

  • Strong Q2: Revenue rose 20% to $312.3M and Adjusted EBITDA more than doubled to $28.6M (9.2% margin), with Center Margin up 34% to $97.8M; management raised full-year revenue, Center Margin, and Adjusted EBITDA guidance and reiterated positive free cash flow for 2024 .
  • Operating momentum: Clinician base grew 14% YoY to 6,984 (net +118 in Q2), visits rose 15% to 2.0M, and total revenue per visit (TRPV) increased 4% to $159; NPS reached 86 and Google reviews averaged 4.6/5, underscoring patient satisfaction .
  • Outlook and near-term cadence: Q3 guide (revenue $290–$310M; Adjusted EBITDA $15–$21M) implies sequential step-down on seasonality and a planned H2 TRPV headwind from one payer, plus incremental investments to support 2025 targets; FY24 guidance raised across all financial metrics .
  • Capital and leverage: Q2 free cash flow was $39M with $87M cash and 2.2x net leverage; management does not intend to raise debt or equity, expecting continued leverage improvement through year-end .
  • Estimates note: S&P Global consensus estimates were unavailable due to API limits; company results landed at the high end of prior Q2 guidance ($297–$315M revenue), supporting a “beat and raise” narrative vs internal targets .

What Went Well and What Went Wrong

  • What Went Well

    • “Seventh consecutive quarter of meeting or exceeding expectations,” with Q2 revenue $312M and Adjusted EBITDA ~$29M; raised guidance across key FY metrics .
    • Operational execution: TRPV +4% YoY to $159 and visit volumes +15% to 2.0M, driving Center Margin +34% to $98M and Adjusted EBITDA +103% to $29M (9.2%) .
    • Cash generation: “Strong free cash flow of $39M” in Q2; $87M cash and net long‑term debt of $279M; “no intention of raising additional debt or equity” .

  • What Went Wrong

    • Sequential Q3 margin step‑down expected (~300 bps at midpoint) due to seasonality (vacation-driven lower visits), H2 TRPV step‑down from one payer, and higher G&A from growth investments .
    • Continued GAAP net loss: Q2 net loss was $(23.3)M (EPS $(0.06)), though improved YoY from $(45.5)M; stock‑based compensation remains a material non‑cash expense .
    • Residual Change Healthcare collections timing: DSO improved to 49 days but payor collections normalization remains an H2 focus (management expects resolution by year‑end) .

Financial Results

MetricQ4 2023Q1 2024Q2 2024
Revenue ($M)$280.6 $300.4 $312.3
Loss from Operations ($M)$(32.3) $(16.8) $(15.9)
Center Margin ($M)$83.3 $94.7 $97.8
Center Margin (% of Revenue)29.7% 31.5% 31.3%
Adjusted EBITDA ($M)$20.3 $27.7 $28.6
Adj. EBITDA Margin (%)7.2% 9.2% 9.2%
Net Loss ($M)$(45.0) $(21.1) $(23.3)

KPIs

KPIQ4 2023Q1 2024Q2 2024
Clinician Base (end of period)6,645 6,866 6,984
Net Clinician Adds (period)227 221 118
Visit Volumes (M)1.8 1.9 2.0
TRPV ($ per visit)$157 $157 $159
Virtual / In‑Person MixN/AN/A71% / 29%
Patient NPS / Google RatingN/ANPS 84; 4.5/5 NPS 86; 4.6/5

Notes: Q2 free cash flow was $39M; operating cash flow in Q2 was $44.1M (H1 total CFO $22.2M, with $44.1M in Q2), reflecting strong collections; the CFO’s FCF figure reflects capex outflows .

Estimates vs Actuals (availability)

  • S&P Global consensus estimates for Q2 2024 were unavailable due to API limits at the time of retrieval; as context, actual Q2 revenue of $312.3M was at the high end of the prior company Q2 guide ($297–$315M) .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueFY 2024$1.19B – $1.24B $1.20B – $1.242B Raised
Center MarginFY 2024$353M – $373M $363M – $383M Raised
Adjusted EBITDAFY 2024$88M – $98M $90M – $100M Raised
Free Cash FlowFY 2024Positive Positive Maintained
RevenueQ3 2024—$290M – $310M New
Center MarginQ3 2024—$83M – $95M New
Adjusted EBITDAQ3 2024—$15M – $21M New
Stock‑Based CompensationFY 2024~$80M – $95M (original guide) Now expected toward lower end of range Lower End
De Novo OpeningsFY 2024No more than 20 Fewer than 10 Lowered

Management also highlighted incremental H2 investments (e.g., business development hires) to strengthen 2025 positioning while maintaining raised FY guidance .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q4’23 and Q1’24)Current Period (Q2’24)Trend
Payer rates & TRPVMulti‑year payer strategy; TRPV +2% in Q4; TRPV +4% in Q1; one large payer to reset rates lower in H2’24; expect low single‑digit TRPV growth for FY24 TRPV $159 (+4% YoY); broad negotiations positive; H2 step‑down from one payer persists; FY25 TRPV expected low single‑digit increase Mixed near‑term; positive LT
Clinician growth & capacity100% organic adds; 2023 net +1,014; incentives to drive full‑time capacity; Q2 adds seasonally lower; Q3 step‑up expected Net +118 adds; pipeline robust; continuing shift to more full‑time; retention slightly better YoY Improving capacity
Digital ops (OBIE/check‑in)OBIE nationwide; piloting digital check‑in; standardizing ops Rolling out digital patient check‑in (6 states live, 5 in process); launching phone digital matching; “One Stance” operating model launched July 1 Scaling deployment
Free cash flow & leveragePositive FCF targeted in 2024; end‑2023 net leverage improved; no incremental capital planned Q2 FCF $39M; DSO 49 days (−4 q/q); net leverage 2.2x; no new debt/equity planned Strengthening
De novos & footprint2023 consolidated 82 centers; ≤20 de novos in 2024 <10 de novos in 2024; ample capacity in current footprint More disciplined
Collections/Change cyberattackQ1: temporary collections disruption; DSO up; normalization expected DSO improved; timing resolution expected by year‑end Normalizing
Modality mixHybrid strategy; mix not detailed Shift to in‑person continues: ~71% virtual / 29% in‑person; +150 bps q/q toward in‑person Gradual in‑person shift
Delegated credentialingPursuing delegation with payers; speeds onboarding Continued progress persuading payers; migration to new credentialing platform Improving

Management Commentary

  • “This is now our seventh consecutive quarter of meeting or exceeding expectations… Based on the strength of the quarter, we are once again raising our full year guidance for all financial metrics.” — Ken Burdick, CEO .
  • “We produced strong top-line results… Visit volumes of 2 million increased 15%… TRPV increased 4% to $159… Adjusted EBITDA of $29 million… We generated a strong free cash flow of $39 million… We have no intention of raising additional debt or equity.” — Dave Bourdon, CFO .
  • “The redesign of the operating model was launched on July 1… standardizing the operational model across our 33 states… already starting to see positive impacts.” — Ken Burdick .
  • “We beat and raised on each of our guided financial metrics for the year… achieved positive free cash flow for the first half of the year.” — Ken Burdick .

Q&A Highlights

  • Payer rates: Negotiations broadly constructive; one outlier payer resetting down remains the exception; focus includes delegated credentialing and, longer‑term, value‑based arrangements .
  • Q3 margin dynamics: Sequential EBITDA margin compression driven by ~half visits (seasonality) and ~half TRPV step‑down, plus higher G&A from investments; revenue midpoint down ~$12M q/q .
  • 2025 targets: Management reaffirmed commitment to exiting 2025 with double‑digit EBITDA margins, mid‑teens revenue growth, and positive FCF; FY24 margin expansion ~220 bps at midpoint .
  • Capacity and retention: Continued shift toward full‑time clinicians; retention slightly better YoY, with robust recruiting pipeline .
  • Credentialing: Migrating to a new platform and pursuing delegated credentialing to accelerate clinician ramp .
  • Footprint: <10 de novos in 2024; significant capacity in existing centers; selective growth where in‑person demand and recruiting are strongest .

Estimates Context

  • S&P Global consensus estimates for Q2 2024 revenue/EPS were unavailable at time of retrieval due to API limits; as an internal benchmark, actual revenue of $312.3M was near the high end of company’s prior Q2 guidance of $297–$315M .
  • Given raised FY24 guidance and commentary on H2 cadence, Street models may need to: (a) increase FY revenue/EBITDA to match new ranges, (b) shift intra‑year weighting toward H1, and (c) incorporate Q3 seasonal/TRPV step‑down and H2 investment spend .

Key Takeaways for Investors

  • Durable growth with operating leverage: Double‑digit organic revenue growth with expanding Center Margin and EBITDA margin (9.2%) supports a trajectory toward double‑digit exit margins in 2025, contingent on continued execution and rate management .
  • Raised FY guide and positive FCF are key supports: FY24 ranges moved up across revenue, Center Margin, and EBITDA; Q2 FCF of $39M and no plans to raise capital reduce balance sheet risk and support sentiment .
  • Near‑term cadence matters: Expect Q3 step‑down (seasonality + TRPV reset + investments); positioning long exposure around potential H2 execution and 2025 setup vs near‑term margin optics is critical .
  • Payer dynamics a focal variable: Broadly positive negotiations with one outlier reset; progress on delegated credentialing and specialty mix (e.g., neuropsych) should support TRPV and margins into 2025 .
  • Hybrid care and in‑person tailwind: Mix is gradually shifting back to in‑person (29%), which may aid collections efficacy and service mix; operational standardization (“One Stance”) and digital tooling should improve throughput and revenue cycle .
  • Execution watch‑items: Monitor DSO normalization, pace of full‑time clinician mix shift, onboarding speed via delegated credentialing, and evidence of operating model benefits in H2 KPIs .
  • Valuation narrative: “Beat and raise” vs internal targets with improving FCF and leverage can be a positive catalyst; model prudently for Q3 seasonality/H2 TRPV headwind and reinvestment .

Appendix: Additional Context and Data Points

  • Q2 non‑GAAP reconciliation highlights include add‑backs for stock‑based comp, litigation, strategic initiatives, and minor real estate items .
  • Cash flow: H1 2024 operating cash flow +$22.2M (Q2 CFO +$44.1M), capex H1 ~$10.2M; Q2 FCF thus consistent with CFO commentary .
  • Marketing/brand: May “Not One Face” campaign to reduce stigma; not financially material to quarter but reinforces brand positioning .

Sources: Q2 2024 press release and financials ; Q2 2024 call transcript –; Q1 2024 press/8‑K highlights ; Q1 2024 call –; Q4 2023 call –. Estimates note: S&P Global consensus data unavailable at retrieval time.